Back to dashboard
CommercialCoverageMedium impact

08.02.49a, Pembrolizumab and berahyaluronidase alfa-pmph (Keytruda QLEX™)

Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Days to comply
—

Summary

A new policy has been established for Pembrolizumab and berahyaluronidase alfa-pmph (Keytruda QLEX™), a combination cancer therapy. This policy will affect billing and coverage determination for this specific pharmaceutical product starting April 1, 2026.

Action Required

Action needed
Before April 1, 2026: Billing team and oncology providers must review the full policy details at the provided URL to understand coverage criteria, prior authorization requirements, and billing procedures for Keytruda QLEX™. Update billing systems and prior authorization workflows as specified in the complete policy documentation.

Related policy hubs